Pharmacokinetic self-potentiation of idarubicin by induction of anthracycline carbonyl reducing enzymes

References

• Bonfante V, Ferrari L, Villani F, Bonadonna G. Phase I study of 4-demethoxydaunorubicin. Invest New Drugs 1983; 1: 161–168
   PubMedGoogle Scholar
• Wiernik P H, Banks P L, Case D C, Jr, Arlin Z A, Periman P O, Todd M B, et al. Cytarabine plus IDA or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313–319
   PubMed Web of Science ®Google Scholar
• Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, et al. Results of a randomized trial comparing IDA and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666–1674
   PubMed Web of Science ®Google Scholar
• Vogler W R, Velez-Garcia E, Weiner R S, Flaum M A, Bartolucci A A, Omura G A, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 1992; 10: 1103–1111
   PubMed Web of Science ®Google Scholar
• Lovless H, Arena E, Felsted R L, Bachur N R. Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res 1978; 38: 593–598
   PubMed Web of Science ®Google Scholar
• Felsted R L, Bachur N R. Human liver daunorubicin reductases. Prog Clin Biol Res 1982; 114: 291–305
   PubMedGoogle Scholar
• Wermuth B, Bohren K M, Heinemann G, von Wartburg J P, Gabbay K H. Human carbonyl reductase. Nucleotide sequence analysis of a cDNA and amino acid sequence of the encoded protein. J Biol Chem 1988; 263: 16185–16188
   PubMed Web of Science ®Google Scholar
• Bohren K M, Bullock B, Wermuth B, Gabbay K H. The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. J Biol Chem 1989; 264: 9547–9551
   PubMed Web of Science ®Google Scholar
• Wirth H, Wermuth B. Immunohistochemical localization of carbonyl reductase in human tissues. J Histochem Cytochem 1992; 40: 1857–1863
   PubMed Web of Science ®Google Scholar
• Forrest G L, Gonzalez B. Carbonyl reductase. Chem Biol Interact 2000; 129: 21–40
   PubMed Web of Science ®Google Scholar
• Kuffel M J, Reid J M, Ames M M. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol 1992; 30: 51–57
   PubMed Web of Science ®Google Scholar
• Le Bot M A, Begue J M, Kernaleguen D, Robert J, Ratanasavanh D, Airiau J, et al. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes. Biochem Pharmacol 1988; 37: 3877–3887
   PubMed Web of Science ®Google Scholar
• Gonzalez B, Akman S, Doroshow J, Rivera H, Kaplan W D, Forrest G L. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. Cancer Res 1995; 55: 4646–4650
   PubMed Web of Science ®Google Scholar
• Soldan M, Netter K J, Maser E. Induction of daunorubicin carbonyl reducing enzymes by daunorubicin in sensitive and resistant pancreas carcinoma cells. Biochem Pharmacol 1996; 51: 117–123
   PubMed Web of Science ®Google Scholar
• Ax W, Soldan M, Koch L, Maser E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol 2000; 59: 293–300
   PubMed Web of Science ®Google Scholar
• Tomida A, Naito M, Tsuruo T. Acute induction of adriamycin-resistance in human colon carcinoma HT-29 cells exposed to a sublethal dose of adriamycin. Cancer Sci 1995; 86: 224–232
   Google Scholar
• Simon S M, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994; 26;91: 3497–3504
   Web of Science ®Google Scholar
• Skovsgaard T, Nielsen D, Maare C, Wassermann K. Cellular resistance to cancer chemotherapy. Int Rev Cytol 1994; 156: 77–157
   PubMed Web of Science ®Google Scholar
• Cole S P, Bhardwaj G, Gerlach J H, Mackie J E, Grant C E, Almquist K C, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650–1654
   PubMed Web of Science ®Google Scholar
• Scheper R J, Broxterman H J, Scheffer G L, Kaaijk P, Dalton W S, van Heijningen T H, et al. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993; 53: 1475–1479
   PubMed Web of Science ®Google Scholar
• Fukushima T, Kawai Y, Urasaki Y, Yoshida A, Ueda T, Nakamura T. Influence of idarubicinol on the antileukemic effect of idarubicin. Leuk Res 1994; 18: 943–947
   PubMed Web of Science ®Google Scholar
• Tamassia V, Pacciarini M A, Moro E, Piazza E, Vago G, Libretti A. Pharmacokinetic study of intravenous and oral idarubicin in cancer patients. Int J Clin Pharmacol Res 1987; 7: 419–426
   PubMedGoogle Scholar
• Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet 1993; 24: 275–288
   PubMed Web of Science ®Google Scholar
• Fukushima T, Yamashita T, Goto N, Ueda T, Okabe K I, Kuraishi Y, et al. A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia. Int J Hematol 2001; 74: 297–302
   PubMed Web of Science ®Google Scholar
• Finkel J M, Knapp K T, Mulligan L T. Fluorometric determination of serum levels and urinary excretion of daunomycin (NSC-82151) in mice and rats. Cancer Chemother Rep 1969; 53: 159–164
   PubMedGoogle Scholar
• Motoji N, Hayama E, Shigematsu A. Studies on the quantitative autoradiography. I. Radioluminography for quantitative autoradiography of 14C. Biol Pharm Bull 1995; 18: 89–93
   PubMed Web of Science ®Google Scholar
• Moro E, Bellotti V, Jannuzzo M G, Stegnjaich S, Valzelli G. High-performance liquid chromatographic method for pharmacokinetic studies on the new anthracycline 4-demethoxydaunorubicin and its 13-dihydro derivative. J Chromatogr 1983; 274: 281–287
   PubMed Web of Science ®Google Scholar
• Camaggi C M, Carisi P, Strocchi E, Pannuti F. High-performance liquid chromatographic analysis of idarubicin and fluorescent metabolites in biological fluids. Cancer Chemother Pharmacol 1992; 30: 303–306
   PubMed Web of Science ®Google Scholar
• Lowry O H, Rosebrough N J, Farr A L, Randall R J. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Kang W, Weiss M. Modeling the metabolism of idarubicin to idarubicinol in rat heart: effect of rutin and phenobarbital. Drug Metab Dispos 2003; 31: 462–468
   PubMed Web of Science ®Google Scholar
• Fukushima T, Ueda T, Uchida M, Nakamura T. Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells. Int J Hematol 1993; 57: 121–130
   PubMed Web of Science ®Google Scholar